Áttétes emlőrák: vizsgálatok itt: Olaszország
70 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 15.. Ask the study team whether a trial fits you.
- 2. fázisNot yet taking people in OlaszországA TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2- NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)
- Where
- Florence, Milan, Naples, Rome
- Életkor
- 18 év and over
- People
- 25 worldwide
- Run by
- Medica Scientia Innovation Research S.L.
See details and how to join2026-525328-10-00 - 3. fázisTaking peopleA Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
- Where
- Aviano, Florence, Meldola, Milan, Naples, Rome
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07205822 · EU 2025-521904-23-00 - 1/2. fázisNot yet taking people in OlaszországA Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- Where
- Aviano, Meldola, Milan, Monza, Padova, Pisa
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT07701941 · EU 2024-517541-14-00 - 3. fázisTaking peoplePalazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Where
- Aviano, Bergamo, Bologna, Genoa, Lecce, Milan, Monza, Naples, Padova, Pisa, Prato, Rome, Rozzano
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00 - 3. fázisTaking peopleStereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
- Where
- Florence, Milan
- Életkor
- 18 év and over
- People
- 345 worldwide
- Run by
- Vastra Gotaland Region
See details and how to joinNCT05377047 - 2. fázisNot yet taking people in OlaszországRoll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
- Where
- Milan, Padova
- People
- 51 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07679269 · EU 2026-525890-38-00 - No phaseTaking peopleTo Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
- Where
- Prato
- People
- 150
- Run by
- Fondazione Sandro Pitigliani
See details and how to joinNCT04660435 - No phaseTaking peopleEORTC Metastatic Breast Cancer Module Development
- Where
- Naples, Padova
- Életkor
- 18 év and over
- People
- 568 worldwide
- Run by
- University of Leeds
See details and how to joinNCT07806266 - 2. fázisNot yet taking people in OlaszországLuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor
- Where
- Meldola, Milan, Naples, Negrar, Reggio Emilia
- Életkor
- 18 év and over
- People
- 36 worldwide
- Run by
- Novartis Pharma AG
See details and how to joinNCT04939610 · EU 2023-508995-12-01 - 1/2. fázisTaking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- Milan, Modena, Naples
- Életkor
- 18 év to 100 év
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - 3. fázisTaking peopleElacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- Where
- Bergamo, Florence, Genoa, Leghorn, Milan, Modena, Monserrato, Monza, Naples, Negrar, Novara, Piacenza, Rome
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- MedSIR
See details and how to joinNCT06382948 · EU 2024-512926-27-00 - No phaseFut, nem toborozDESTINY Breast Respond HER2-(Ultra)Low Europe
- Where
- Alessandria, Chieti, Città di Castello, Empoli, Lecce, Lecco, Legnago, Legnano, Meldola, Modena, Monza, Naples, Novara, Padova, Palermo, Pavia, Pisa, Potenza, Province of Macerata, Reggio Calabria, Reggio Emilia, Roma, Salerno, San Giovanni Rotondo, Sassari, Taormina, Torino, Treviso, Udine, Varese
- Életkor
- 18 év and over
- People
- 2295 worldwide
- Run by
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
See details and how to joinNCT05945732 - No phaseBefejeződöttAURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
- Where
- Biella, Bolzano, Carpi, Genova, Legnago, Milan, Parma, Pavia, Reggio Emilia
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Jules Bordet Institute
See details and how to joinNCT02102165 - 2. fázisTaking peopleSafety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
- Where
- Ancona, Aviano, Florence, Genoa, Macerata, Milan, Modena, Monza, Naples, Negrar, Novara, Padova, Piacenza, Rome
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- MedSIR
See details and how to joinNCT06486883 · EU 2024-512360-55-00 - 1/2. fázisTaking peopleFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Where
- Alexandria, Brescia, Milan, Monza, Pisa, Ravenna, Rome, Verona
- Életkor
- 18 év and over
- People
- 880 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00 - 1. fázisTaking peopleFirst-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer
- Where
- Milan, Monza, Rozzano
- Életkor
- 18 év and over
- People
- 145 worldwide
- Run by
- Onkure Inc.
See details and how to join2023-508435-31-00 - 2. fázisTaking people“A Phase II trial of atezolizumab plus CArboplatin plus nab-Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive breast cancer patients”
- Where
- Avellino, Aviano, Bologna, Cuneo, Faenza, Genoa, Meldola, Naples, Parma, Pozzuoli, Reggio Emilia, Rimini, Roma, Terni, Turin, Vicenza, Ospedale S. Timoteo di Termoli
- Életkor
- 18 év and over
- People
- 104
- Run by
- Consorzio Oncotech
See details and how to join2024-519514-31-00 - 2. fázisTaking peopleA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- Where
- Cremona
- Életkor
- 18 év and over
- People
- 37 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT04641247 · EU 2023-506618-29-00 - No phaseTaking peopleEmotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
- Where
- Ancona, Aviano, Bagno a Ripoli, Bari, Bergamo, Brescia, Brindisi, Busto Arsizio, Como, Florence, Genova, Messina, Milan, Modena, Naples, Novara, Palermo, Pavia, Pisa, Prato, Rimini, Roma, Rome, Sassari, Verduno, Verona, Vimercate
- Életkor
- 18 év and over
- People
- 1000
- Run by
- European Institute of Oncology
See details and how to joinNCT06994377 - 3. fázisFut, nem toborozTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
- Where
- Bari, Bologna, Genoa, Milan, Misterbianco, Naples, Padova, Prato, Rome, Trento
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT05950945 · EU 2023-505616-38-00 - 1/2. fázisTaking peopleBeamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps people with different types of HER2+ cancer that has spread
- Where
- Ancona, Candiolo, Meldola, Milan, Misterbianco, Naples, Rozzano
- Életkor
- 18 év and over
- People
- 181 worldwide
- Run by
- Boehringer Ingelheim International GmbH
See details and how to join2023-509566-38-00 - 1/2. fázisTaking peopleStudy of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors
- Where
- Milan
- Életkor
- 18 év and over
- People
- 55 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521911-38-00 - 2. fázisTaking peopleElacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)
- Where
- Milan
- Életkor
- 18 év and over
- People
- 26
- Run by
- European Institute of Oncology
See details and how to joinNCT07395336 - 1. fázisTaking peoplePhase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.
- Where
- Milan, Reggio Emilia
- Életkor
- 18 év and over
- People
- 76 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2023-510356-23-00 - 2. fázisNot yet taking people in OlaszországA multicenter, multicohort, phase 2 platform trial to personalize second-line treatment intensity and targeting in HR-positive, HER2-negative metastatic breast cancer through an integrated liquid biopsy algorithm.
- Where
- Aviano, Meldola, Misterbianco, Rome, Vicenza
- Életkor
- 18 év and over
- People
- 159
- Run by
- Centro Di Riferimento Oncologico Di Aviano
See details and how to join2025-523460-21-00